Down regulation of antigen presentation pathway plays an important role in metastasis and progression of advanced stage of epithelial ovarian cancer.
Project/Area Number |
21390449
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Niigata University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
YAHATA Tetsuro 新潟大学, 医歯学系, 准教授 (90293232)
YOSHIHARA Kousuke 新潟大学, 医歯学系, 助教 (40547535)
SEKINE Masayuki 新潟大学, 医歯学総合病院, 助教 (70345502)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2010: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2009: ¥12,090,000 (Direct Cost: ¥9,300,000、Indirect Cost: ¥2,790,000)
|
Keywords | 卵巣がん / EMT / 抗原提供 / 遺伝子発現プロファイル / 上皮性卵巣がん / 予後予測 / 腫瘍内浸潤リンパ球 / 上皮性卵巣癌 / 分子標的治療薬 / 上皮間葉移行 |
Research Abstract |
High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies using EMT molecules for high-risk patients. This risk classification based on the gene expression signature is an accurate predictor of clinical outcome in patients with advanced stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients.
|
Report
(4 results)
Research Products
(16 results)